Author Title Type [ Year(Asc)]
Filters: Author is Konopleva, Marina  [Clear All Filters]
Srour, S.A., Saliba, R.M., Bittencourt, M.Cb, Perez, J.Miguel Ram, Kongtim, P., Alousi, A., Al-Atrash, G., Olson, A., Betul, O., Mehta, R., et al. (2019). Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.Am J Hematol.
Ravandi, F., Assi, R., Daver, N., Benton, C.B., Kadia, T., Thompson, P.A., Borthakur, G., Alvarado, Y., Jabbour, E.J., Konopleva, M., et al. (2019). Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.Lancet Haematol.
Dalle, I.Abou, Kantarjian, H.M., Short, N.J., Konopleva, M., Jain, N., Garcia-Manero, G., Garris, R., Qiao, W., Cortes, J.E., O'Brien, S., et al. (2019). Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.Am J Hematol.
Zeng, Z., Liu, W., Benton, C.B., Konoplev, S., Lu, H., Wang, R.-Y., Chen, J., Shpall, E., Baggerly, K.A., Champlin, R., et al. (2019). Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.Acta Haematol1-9.
Pemmaraju, N., Lane, A.A., Sweet, K.L., Stein, A.S., Vasu, S., Blum, W., Rizzieri, D.A., Wang, E.S., Duvic, M., J Sloan, M., et al. (2019). Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.N Engl J Med380, 1628-1637.
Takahashi, K., Kantarjian, H., Garcia-Manero, G., Borthakur, G., Kadia, T., DiNardo, C., Jabbour, E., Pierce, S., Estrov, Z., Konopleva, M., et al. (2015). Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.Clin Lymphoma Myeloma Leuk.
Daver, N., Thomas, D., Ravandi, F., Cortes, J., Garris, R., Jabbour, E., Garcia-Manero, G., Borthakur, G., Kadia, T., Rytting, M., et al. (2015). Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia.Haematologica.
Sasaki, K., Strom, S.S., O'Brien, S., Jabbour, E., Ravandi, F., Konopleva, M., Borthakur, G., Pemmaraju, N., Daver, N., Jain, P., et al. (2015). Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.Lancet Haematol2, e186-93.
Han, L., Qiu, P., Zeng, Z., Jorgensen, J.L., Mak, D.H., Burks, J.K., Schober, W., McQueen, T.J., Cortes, J., Tanner, S.D., et al. (2015). Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.Cytometry A.
Carter, B.Z., Mak, P.Yee, Mak, D.H., Ruvolo, V.R., Schober, W., McQueen, T., Cortes, J., Kantarjian, H.M., Champlin, R.E., Konopleva, M., et al. (2015). Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.Oncotarget.